Consolidated Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Consolidated Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-63,610	Closed	-$1.8M	–	49
2022 Q4	$1.8M	Sell	63,610 -14,338	-18%	-$455K	1.07%	36
2022 Q3	$2.56M	Buy	77,948 +21,037	+37%	+$772K	1.61%	19
2022 Q2	$1.79M	Sell	56,911 -26,218	-32%	-$917K	1.07%	32
2022 Q1	$3.82M	Buy	83,129 +32,111	+63%	+$1.53M	1.73%	26
2021 Q4	$3.12M	Buy	51,018 +2,549	+5%	+$176K	1.38%	25
2021 Q3	$3.62M	Buy	48,469 +2,063	+4%	+$173K	1.7%	25
2021 Q2	$4.29M	Sell	46,406 -7,023	-13%	-$597K	1.98%	23
2021 Q1	$4.74M	Buy	+53,429	New	+$5.3M	2.36%	20

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Consolidated Capital Management's ARKG Position: Q1 2023 in Review

Consolidated Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2023, closing a stake of 63,610 shares — an estimated $1.8M sold.

Consolidated Capital Management first reported a position in ARKG in Q1 2021 and held it in 8 quarters. The position peaked at $4.74M in Q1 2021. 295 funds tracked by Wall St. Rank hold ARKG as of Q1 2023.

Consolidated Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2023 after selling out during the quarter.
Consolidated Capital Management sold 63,610 ARK Genomic Revolution ETF shares in Q1 2023, an estimated $1.8M.
Consolidated Capital Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 8 quarters.
Consolidated Capital Management's ARK Genomic Revolution ETF position peaked at $4.74M in Q1 2021.
295 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2023.

Based on Consolidated Capital Management's 13F filing for Q1 2023, filed 11 Apr 2023.